Abstract
Introduction: Chronic low-grade inflammation is suggested to play a pathophysiological role in bipolar disorder (BD) and its related cognitive dysfunctions. Although kynurenine (KYN) pathway metabolites are key inflammatory mediators, studies investigating the association between KYN metabolism and cognition in BD are scarce. We aimed to explore the relationship between KYN metabolism and cognitive functioning across different mood states in BD. Methods: Sixty-seven patients with BD (35 depressed and 32 [hypo] manic) and 29 healthy controls were included. Cognitive functioning was assessed at 3 time intervals (baseline, 4, and 8 months) assessing processing speed, sustained attention, verbal memory, working memory, and response inhibition. Plasma samples for quantification of 3-hydroxykynurenine, quinolinic acid, and kynurenic acid (KYNA) were concurrently provided. Linear mixed models were used for statistical analysis. Results: The manic group showed deficits in all assessed cognitive domains with the exception of verbal memory at all test moments. The bipolar depression group showed deficits in the processing speed at all test moments. Throughout the whole follow-up period, KYNA was significantly lower in both patient groups than in controls. Only in the bipolar depression group, low KYNA was associated with worse global cognitive functioning (B = 0.114, p = 0.02) and slower processing speed in particular (B = 0.139, p = 0.03). Conclusion: Only in the bipolar depression group, lower KYNA was associated with worse cognitive functioning. Future large-scale longitudinal studies are warranted to confirm the role of KYN metabolites in cognitive impairment in patients with BD and the possible therapeutic implications of this relationship.
References
1.
Brissos
S
, Dias
VV
, Kapczinski
F
. Cognitive performance and quality of life in bipolar disorder
. Can J Psychiatry
. 2008
;53
(8
):517
–24
. .2.
Martínez-Arán
A
, Vieta
E
, Reinares
M
, Colom
F
, Torrent
C
, Sánchez-Moreno
J
, Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder
. Am J Psychiatry
. 2004 Feb
;161
(2
):262
–70
. .3.
Ceylan
D
, Akdede
BB
, Bora
E
, Aktener
AY
, Hıdıroğlu Ongun
C
, Tunca
Z
, Neurocognitive functioning during symptomatic states and remission in bipolar disorder and schizophrenia: a comparative study
. Psychiatry Res
. 2020 Oct 1
;292
:113292
. .4.
Bora
E
, Yücel
M
, Pantelis
C
, Berk
M
. Meta-analytic review of neurocognition in bipolar II disorder
. Acta Psychiatr Scand
. 2011
;123
:165
–74
. .5.
Arts
B
, Jabben
N
, Krabbendam
L
, van Os
J
. Meta-analyses of cognitive functioning in euthymic bipolar patients and their first-degree relatives
. Psychol Med
. 2008 Jun 9
;38
(6
):771
–85
. .6.
Kurtz
MM
, Gerraty
RT
. A meta-analytic investigation of neurocognitive deficits in bipolar illness: profile and effects of clinical state
. Neuropsychology
. 2009
;23
(5
):551
–62
. .7.
Bora
E
. Differences in cognitive impairment between schizophrenia and bipolar disorder: Considering the role of heterogeneity
. J Affect Disord
. 2018
.8.
Van Rheenen
T
, Lewandowski
K
, Tan
E
, Ospina
L
, Ongur
D
, Neill
E
. Characterizing cognitive heterogeneity on the schizophrenia-bipolar disorder spectrum.
Psychol Med
. 2017
;47
(10
):1848
–64
.9.
Bora
E
. Neurocognitive features in clinical subgroups of bipolar disorder: a meta-analysis
. J Affect Disord
. 2018
;229
:125
–34
. Elsevier B.V. .10.
Cardoso
T
, Bauer
IE
, Meyer
TD
, Kapczinski
F
, Soares
JC
. Neuroprogression and cognitive functioning in bipolar disorder: a systematic review
. Curr Psychiatry Rep
. 2015
;17
:75
. Current Medicine Group LLC 1.11.
Lewandowski
KE
, Cohen
BM
, Öngur
D
. Evolution of neuropsychological dysfunction during the course of schizophrenia and bipolar disorder
. Psychol Med
. 2011 Feb
;41
(2
):225
–41
. .12.
Berk
M
, Kapczinski
F
, Andreazza
AC
, Dean
OM
, Giorlando
F
, Maes
M
, Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors
. Neurosci Biobehav Rev
. 2011
;35
:804
–17
. .13.
Berk
M
, Post
R
, Ratheesh
A
, Gliddon
E
, Singh
A
, Vieta
E
, Staging in bipolar disorder: from theoretical framework to clinical utility
. World Psychiatry
. 2017 Oct 1
;16
(3
):236
–44
. .14.
Szmulewicz
A
, Valerio
MP
, Martino
DJ
. Longitudinal analysis of cognitive performances in recent-onset and late-life bipolar disorder: a systematic review and meta-analysis
. Bipolar Disord
. 2020 Feb 2
;22
(1
):28
–37
.15.
Bartoli
F
, Misiak
B
, Callovini
T
, Cavaleri
D
, Cioni
RM
, Crocamo
C
, The kynurenine pathway in bipolar disorder: a meta-analysis on the peripheral blood levels of tryptophan and related metabolites
. Mol Psychiatry
. 2020
;26
(7
):3419
–29
.16.
Savitz
J
. The kynurenine pathway: a finger in every pie
. Mol Psychiatry
. 2020
;25
:131
–47
. .17.
Alexander
KS
, Wu
HQ
, Schwarcz
R
, Bruno
JP
. Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine
. Psychopharmacology
. 2012 Apr
;220
(3
):627
–37
. .18.
Erhardt
S
, Schwieler
L
, Emanuelsson
C
, Geyer
M
. Endogenous kynurenic acid disrupts prepulse inhibition
. Biol Psychiatry
. 2004 Aug 15
;56
(4
):255
–60
. .19.
Solvang
SH
, Nordrehaug
JE
, Tell
GS
, Nygård
O
, McCann
A
, Ueland
PM
, The kynurenine pathway and cognitive performance in community-dwelling older adults. The Hordaland Health Study
. Brain Behav Immun
. 2019 Jan 1
;75
:155
–62
. .20.
Zhou
Y
, Zheng
W
, Liu
W
, Wang
C
, Zhan
Y
, Li
H
, Cross-sectional relationship between kynurenine pathway metabolites and cognitive function in major depressive disorder
. Psychoneuroendocrinology
. 2019 Mar 1
;101
:72
–9
. .21.
Young
KD
, Drevets
WC
, Dantzer
R
, Teague
TK
, Bodurka
J
, Savitz
J
. Kynurenine pathway metabolites are associated with hippocampal activity during autobiographical memory recall in patients with depression
. Brain Behav Immun
. 2016 Aug 1
;56
:335
–42
. .22.
Platzer
M
, Dalkner
N
, Fellendorf
FT
, Birner
A
, Bengesser
SA
, Queissner
R
, Tryptophan breakdown and cognition in bipolar disorder
. Psychoneuroendocrinology
. 2017 Jul
;81
:144
–50
. .23.
Marx
W
, McGuinness
AJ
, Rocks
T
, Ruusunen
A
, Cleminson
J
, Walker
AJ
, The kynurenine pathway in major depressive disorder, bipolar disorder, and schizophrenia: a meta-analysis of 101 studies
. Mol Psychiatry
. 2020
. Epub ahead of print. .24.
van den Ameele
S
, van Nuijs
AL
, Lai
FY
, Schuermans
J
, Verkerk
R
, van Diermen
L
, A mood state-specific interaction between kynurenine metabolism and inflammation is present in bipolar disorder
. Bipolar Disord
. 2019 Feb
;22
(1
):59
–69
. .25.
Lecrubier
Y
, Sheehan
D
, Weiller
E
, Amorim
P
, Bonora
I
, Sheehan
KH
, The mini international neuropsychiatric interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI
. Eur Psychiatry
. 1997 Jan 1
;12
(5
):224
–31
. .26.
Trajković
G
, Starčević
V
, Latas
M
, Leštarević
M
, Ille
T
, Bukumirić
Z
, Reliability of the Hamilton rating scale for depression: a meta-analysis over a period of 49 years
. Psychiatry Res
. 2011 Aug 30
;189
(1
):1
–9
. .27.
Young
RC
, Biggs
JT
, Ziegler
VE
, Meyer
DA
. A rating scale for mania: reliability, validity and sensitivity
. Br J Psychiatry
. 1978 Nov
;133
:429
–35
. .28.
Zimmerman
M
, Martinez
JH
, Young
D
, Chelminski
I
, Dalrymple
K
. Severity classification on the Hamilton depression rating scale
. J Affect Disord
. 2013 Sep 5
;150
(2
):384
–8
. .29.
Vieta
E
. Guide to assessment scales in bipolar disorder
. Tarporley
: Springer Healthcare Ltd
; 2010
.30.
Kay
SR
, Fiszbein
A
, Opler
LA
. The positive and negative syndrome scale (PANSS) for schizophrenia
. Schizophr Bull
. 1987
;13
(2
):261
–76
. .31.
van den Ameele
S
, Fuchs
D
, Coppens
V
, de Boer
P
, Timmers
M
, Sabbe
B
, Markers of inflammation and monoamine metabolism indicate accelerated aging in bipolar disorder
. Front Psychiatry
. 2018
;9
:250
. .32.
Erhardt
S
, Schwieler
L
, Imbeault
S
, Engberg
G
. The kynurenine pathway in schizophrenia and bipolar disorder
. Neuropharmacology
. 2017
;112
:297
–306
. .33.
Savitz
J
, Drevets
WC
, Smith
CM
, Victor
TA
, Wurfel
BE
, Bellgowan
PS
, Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder
. Neuropsychopharmacology
. 2015
;40
(2
):463
–71
. .34.
Fourrier
C
, Singhal
G
, Baune
BT
. Neuroinflammation and cognition across psychiatric conditions
. CNS Spectr
. 2019
;24
(1
):4
–15
. .35.
De Picker
L
, Fransen
E
, Coppens
V
, Timmers
M
, de Boer
P
, Oberacher
H
, Immune and neuroendocrine trait and state markers in psychotic illness: decreased kynurenines marking psychotic exacerbations
. Front Immunol
. 2020 Jan 17
;10
:2971
. https://pubmed.ncbi.nlm.nih.gov/32010121/36.
Miskowiak
KW
, Burdick
KE
, Martinez-Aran
A
, Bonnin
CM
, Bowie
CR
, Carvalho
AF
, Methodological recommendations for cognition trials in bipolar disorder by the International Society for Bipolar Disorders Targeting Cognition Task Force
. Bipolar Disord
. 2017 Dec 1
;19
(8
):614
–26
. .© 2021 S. Karger AG, Basel
2021
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
